Lynparza and Imfinzi combination recommended for approval in the EU by CHMP for recurrent endometrial cancer
Imfinzi also recommended for patients with mismatch repair deficient disease
Imfinzi also recommended for patients with mismatch repair deficient disease
India's healthcare sector anticipates telemedicine reaching US$ 5.4 billion by 2025, with AI growing at 45% by 2024 and Healthtech jobs increasing 15-20%
Approval based on DUO-E trial results, which showed Imfinzi reduced the risk of disease progression or death by 58% vs. chemotherapy
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
Subscribe To Our Newsletter & Stay Updated